Clinical Impact of RANK Signalling in Ovarian Cancer

Clinical Impact of RANK Signalling in Ovarian Cancer

Ovarian cancer (OC) is a gynaecological malignancy with poor clinical outcome and limited treatment options. The receptor activator of nuclear factor-κB (RANK) pathway, activated by RANK ligand (RANKL), critically controls bone metabolism, tumourigenesis and tumour immune responses. Denosum...

Full description

Bibliographic Details
Main Authors: Verena Wieser, Susanne Sprung, Irina Tsibulak, Johannes Haybaeck, Hubert Hackl, Heidelinde Fiegl, Christian Marth, Alain Gustave Zeimet
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Cancers
Subjects:
RANKL
RANK
OPG
inflammation
ovarian cancer
denosumab
Online Access:https://www.mdpi.com/2072-6694/11/6/791

Internet

https://www.mdpi.com/2072-6694/11/6/791

Similar Items